AKBLF (Alk-Abello AS) Common Stock: $17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKBLF Alk-Abello AS AKBLF
90 GF Score
Price $40.65
GF Value $31.60
Valuation Modestly Overvalued
View Full Analysis

What is Alk-Abello AS Common Stock?

Alk-Abello AS AKBLF +4.53% 90 Common Stock is $17 Mil as of Mar. 2026. GuruFocus rates AKBLF with a GF Score™ of 90/100 and a GF Value™ of $31.60 (Modestly Overvalued).

Alk-Abello AS's quarterly common stock declined from Sep. 2025 ($17 Mil) to Dec. 2025 ($17 Mil) and declined from Dec. 2025 ($17 Mil) to Mar. 2026 ($17 Mil).

Alk-Abello AS's annual common stock declined from Dec. 2023 ($16 Mil) to Dec. 2024 ($16 Mil) but then increased from Dec. 2024 ($16 Mil) to Dec. 2025 ($17 Mil).

Alk-Abello AS Common Stock Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS Common Stock Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.87 15.81 16.24 15.59 17.40

Alk-Abello AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.09 17.16 17.46 17.40 17.17
AKBLF
90GF Score
Alk-Abello AS AKBLF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alk-Abello AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $17 Mil mean?
Alk-Abello AS (AKBLF) has a Common Stock of $17 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Alk-Abello AS and its competitors.
Is Alk-Abello AS's Common Stock too high?
Alk-Abello AS's current Common Stock is $17 Mil. Overall, Alk-Abello AS has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Common Stock compare to VRTX and REGN?
Alk-Abello AS's Common Stock of $17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current Common Stock is $17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (AKBLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $31.60, compared to a current price of $40.65 — trading 28.6% above its estimated fair value. The current Common Stock is $17 Mil. Alk-Abello AS's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Alk-Abello AS (AKBLF), the current Common Stock is $17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (AKBLF) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of $40.65 is trading 28.6% above its estimated GF Value™ of $31.60. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for AKBLF:

  • Common Stock: $17 Mil
  • GF Value™: $31.60 vs. price of $40.65 (28.6% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the AKBLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
90GF Score

Get the complete analysis for AKBLF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.65
Price
$31.60
GF Value